GLP-1 injection tutorials on TikTok: what creators get right and wrong

What's this video probably claiming?

Based on the caption and hashtag context, @katiemakena is walking viewers through subcutaneous GLP-1 injection technique, likely covering site selection, needle angle, pinching skin, and the psychological hurdle of self-injecting for the first time. The TrimRx affiliate link in the bio signals this is almost certainly compounded semaglutide or tirzepatide, not a branded FDA-approved product. The hashtags for endometriosis, PCOS, and inflammation relief are doing a lot of heavy lifting here. They're implying therapeutic benefit for those conditions beyond the FDA-approved indications of type 2 diabetes and chronic weight management. That framing is worth scrutinizing carefully, because injection technique advice is one thing, but casually pairing GLP-1 promotion with "inflammationrelief" and PCOS community tags nudges viewers toward believing these drugs are treatments for those conditions in a clinical sense, which the evidence does not fully support.

What does the science actually show?

On injection technique itself, the clinical guidance is reasonably straightforward. Subcutaneous injections into the abdomen, thigh, or upper arm are standard, and rotating sites reduces lipohypertrophy. The FDA-approved semaglutide dose titration for weight management (Wegovy) starts at 0.25 mg weekly and escalates over 16 to 20 weeks to 2.4 mg, per the STEP 1 trial (Wilding et al., 2021, NEJM), which showed 14.9% mean body weight reduction over 68 weeks. On PCOS, a 2023 randomized trial by Jensterle et al. in Diabetes Care showed liraglutide improved menstrual regularity and androgen levels, but sample sizes were small and effects were modest. On endometriosis and GLP-1s specifically, the clinical evidence is nearly nonexistent. One 2023 preclinical study (Chrysostomou et al., Journal of Clinical Medicine) explored GLP-1 receptor expression in endometrial tissue, but there are no completed RCTs in humans showing GLP-1 agonists treat endometriosis.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 content and clinical reality is wide in a few specific places. First, the normalization of compounded GLP-1 products. The FDA issued warnings in 2024 and early 2025 about compounded semaglutide quality and dosing inconsistencies, and compounded versions are not bioequivalent substitutes for Wegovy or Ozempic under federal law. Presenting a compounded product injection tutorial as routine medical self-care glosses over real regulatory and safety distinctions. Second, the "inflammationrelief" framing. While GLP-1 receptor agonists do appear to have anti-inflammatory properties in metabolic tissue, per a 2022 review by Rakipovski et al. in Cardiovascular Diabetology, these effects were studied in cardiovascular disease contexts, not as a general anti-inflammatory use case for conditions like endometriosis. Third, the "it gets easier" reassurance, while emotionally valid, can minimize the importance of proper medical supervision for dose titration and side effect monitoring, particularly gastrointestinal adverse events that affected roughly 44% of participants in STEP 1.

What should you actually know?

If you're genuinely considering a GLP-1 agonist, a few things matter more than injection confidence. The product source matters enormously. Compounded semaglutide is not the same as Wegovy or Ozempic, and the FDA removed most compounded semaglutide from the market in 2025 after resolving the shortage designation, though legal challenges have complicated enforcement. The PCOS connection has some legitimate emerging research behind it, but it is not an FDA-approved indication and the evidence base is thin. The endometriosis connection is speculative at this stage. Injection technique tutorials can be genuinely useful for reducing anxiety around self-administration, but they are not a substitute for a prescribing clinician walking you through your specific product, dose, and storage requirements. If a TikTok creator's bio link is selling you the drug they're demonstrating, that is a conflict of interest worth factoring into how you weight their advice.